Applikon Biotechnology Announces Distribution Agreement with InDevR
News Dec 13, 2010
The Virus Counter provides a direct measurement of virus particle concentration within minutes. Unlike conventional plaque titer assays, which take days to complete, the Virus Counter provides accurate and quantitative results in less than 10 minutes. The instrument requires minimal technical training and its small footprint makes it an easy addition to the lab.
The Virus Counter is a unique, "personal" flow cytometer designed specifically for virus quantification. Similar to virus concentration determined by transmission electron microscopy (TEM), the Virus Counter provides a measurement of the total number of virus particles per mL (vp/mL). Unlike TEM however, the assay can be completed in minutes by lab personnel at a per sample cost ~1,000x lower than for TEM.
John Chory, President of Applikon Biotechnology, commented, "The Virus Counter is an important and exciting addition to Applikon's portfolio of upstream products. The Virus Counter is a significant innovation that dramatically changes the way researchers quantify virus samples. Analysis that used to take days to complete now takes minutes and can done be for a small fraction of the cost of alternative methods. Applikon is pleased to work with InDevR to bring this key product to market. InDevR has an innovative approach to process challenges and this fits in nicely with Applikon's goal of providing novel solutions for its customers."
Dr. Kathy Rowlen, CEO of InDevR, states, "We are tremendously excited to be working with Applikon to distribute our Virus Counter. InDevR's strong product development capability is complemented by Applikon's 25 year history supplying and supporting innovative products used in biotechnology laboratories. Applikon has a strong technical service and customer support capability that adds significant value to our relationship and will ensure that end-users will be well supported."
Almost 95% of people with early-diagnosed breast cancer will require surgery and it’s often the first line of treatment for people with brain tumors, for example. But despite improvements in surgical techniques over the past decade, the cancer often comes back after the procedure. Now, a team has developed a spray gel embedded with immune-boosting drugs that could help.READ MORE